Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 124,670 shares at $43.28 ($5.5M) on 2023-03-10, disclosed to the SEC on 2023-03-13.
Open-market sale of $5.5M ITCI by Chairman, President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.51 | 6,805 | $289K | 5.3% |
| 2 | $42.51 | 6,805 | $289K | 5.3% |
| 3 | $43.28 | 34,965 | $1.5M | 27.7% |
| 4 | $43.28 | 34,965 | $1.5M | 27.7% |
| 5 | $44.08 | 1,412 | $62K | 1.1% |
| 6 | $44.08 | 1,412 |
| $62K |
| 1.1% |
| 7 | $45.06 | 19,153 | $863K | 15.8% |
| 8 | $45.06 | 19,153 | $863K | 15.8% |
| Total | $43.76 avg | 124,670 | $5.5M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |